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Abstract Several chronic neurodegenerative disorders
manifest deposits of misfolded or aggregated proteins.
Genetic mutations are the root cause for protein misfolding
in rare families, but the majority of patients have sporadic
forms possibly related to environmental factors. In some
cases, the ubiquitin-proteasome system or molecular
chaperones can prevent accumulation of aberrantly folded
proteins. Recent studies suggest that generation of exces-
sive nitric oxide (NO) and reactive oxygen species (ROS),
in part due to overactivity of the NMDA-subtype of glu-
tamate receptor, can mediate protein misfolding in the
absence of genetic predisposition. S-Nitrosylation, or
covalent reaction of NO with specific protein thiol groups,
represents one mechanism contributing to NO-induced
protein misfolding and neurotoxicity. Here, we present
evidence suggesting that NO contributes to protein mis-
folding via S-nitrosylating protein-disulfide isomerase or
the E3 ubiquitin ligase parkin. We discuss how memantine/
NitroMemantine can inhibit excessive NMDA receptor
activity to ameliorate NO production, protein misfolding,
and neurodegeneration.
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Introduction
Many neurodegenerative diseases are characterized by the
accumulation of misfolded proteins that adversely affect
neuronal connectivity and plasticity, and trigger cell death
signaling pathways [1, 2]. For example, degenerating brain
contains aberrant accumulations of misfolded, aggregated
proteins, such as a-synuclein and synphilin-1 in Parkin-
son’s disease (PD), and amyloid-b (Ab) and tau in
Alzheimer’s disease (AD). The inclusions observed in PD
are called Lewy bodies and are mostly found in the cyto-
plasm. AD brains show intracellular neurofibrillary tangles,
which contain hyperphosphorylated tau, and extracellular
plaques, which contain Ab. These aggregates may consist
of oligomeric complexes of non-native secondary struc-
tures, and demonstrate poor solubility in aqueous or
detergent solvent. Other disorders manifesting protein
aggregation include Huntington’s disease (a polyQ disor-
der), amyotrophic lateral sclerosis (ALS), and prion disease
[3]. The aforementioned disorders are also termed ‘‘con-
formational diseases’’ because of the emergence of protein
aggregation in the brain [4].
An additional feature of most neurodegenerative dis-
eases is excessive generation of reactive nitrogen species
(RNS) and reactive oxygen species (ROS), which can
contribute to neuronal cell injury and death [5–9]. While
many intra- and extra-cellular molecules may participate in
neuronal injury, accumulation of nitrosative stress due to
excessive generation of nitric oxide (NO) appears to be a
potential factor contributing to neuronal cell damage and
death [10, 11]. A well-established model for NO produc-
tion entails a central role of the N-methyl-D-aspartate
(NMDA)-type glutamate receptors in nervous system.
Excessive activation of NMDA receptors drives Ca2?
influx, which in turn activates neuronal NO synthase
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(nNOS) as well as the generation of ROS [12, 13]. Accu-
mulating evidence suggests that NO can mediate both
protective and neurotoxic effects by reacting with cysteine
residues of target proteins to form S-nitrosothiols (SNOs), a
process termed S-nitrosylation because of its effects on the
chemical biology of protein function. Importantly, normal
mitochondrial respiration may also generate free radicals,
principally ROS, and one such molecule, superoxide anion
(O2
-), reacts rapidly with free radical NO to form the very
toxic product peroxynitrite (ONOO-) [14, 15].
Importantly, protein aggregation can result from either (1)
a rare mutation in the disease-related gene encoding the
protein, or (2) posttranslational changes to the protein
engendered by nitrosative/oxidative stress, which may well
account for the more common sporadic cases of the disease
[16]. Therefore, a key theme of this article is the hypothesis
that nitrosative and oxidative stress contribute to protein
misfolding in the brains of the majority of neurodegenerative
patients. In this review, we discuss specific examples
showing that S-nitrosylation of (1) ubiquitin E3 ligases such
as parkin or (2) endoplasmic reticulum chaperones such as
protein-disulfide isomerase (PDI) is critical for the accu-
mulation of misfolded proteins in neurodegenerative
diseases such as PD and other conditions [17–20]. We also
discuss the neuroprotective mechanism of action of NMDA
open-channel blockers like memantine and NO-related
drugs for the treatment of neurodegenerative disorders
[11, 21].
Protein misfolding and aggregation
in neurodegenerative diseases
In general, protein aggregates do not accumulate in
unstressed, healthy neurons due in part to the existence of
cellular ‘quality control machineries.’ For example, molec-
ular chaperones are believed to provide a defense mechanism
against the toxicity of misfolded proteins because chaper-
ones can prevent inappropriate interactions within and
between polypeptides, and can promote refolding of proteins
that have been misfolded because of cell stress. In addition to
the quality control of proteins provided by molecular chap-
erones, the ubiquitin-proteasome system (UPS) and
autophagy/lysosomal degradation are involved in the clear-
ance of abnormal or aberrant proteins. When chaperones
cannot repair misfolded proteins, they may be tagged via
addition of polyubiquitin chains for degradation by the
proteasome. In neurodegenerative conditions, intra- or extra-
cellular protein aggregates are thought to accumulate in the
brain as a result of a decrease in molecular chaperone or
proteasome activities (Fig. 1). In fact, several mutations that
disturb the activity of molecular chaperones or UPS-asso-
ciated enzymes can cause neurodegeneration [2, 22, 23].
Along these lines, postmortem samples from the substantia
nigra of PD patients (versus non-PD controls) manifest a
significant reduction in proteasome activity [24]. Moreover,
overexpression of the molecular chaperone HSP70 can pre-
vent neurodegeneration in vivo in models of PD [25].
Historically, lesions that contain aggregated proteins
were considered to be pathogenic. Recently, several lines
of evidence have suggested that aggregates are formed
through a complex multi-step process by which misfolded
proteins assemble into inclusion bodies; currently, soluble
(micro-) oligomers of these aberrant proteins are thought to
be the most toxic forms via interference with normal cell
activities, while frank macroscopic aggregates may be an
attempt by the cell to wall off potentially toxic material
[12, 26]. Additionally, at least in yeast and cell culture
models, highly toxic aggregates accumulate in a perivac-
uolar compartment where the autophagic pathway
catalyzes clearance of aggresomes. Relatively less-toxic
misfolded proteins are sequestered in juxtanuclear inclu-
sions, which often contain molecular chaperones and
proteasomes as part of the quality control machinery [27].
NMDA receptor-mediated glutamatergic signaling
pathways induce Ca21 influx and generation
of RNS/ROS
It is well known that the amino-acid glutamate is the major
excitatory neurotransmitter in the brain. Glutamate is pres-
ent in high concentrations in the adult central nervous
system and is released for milliseconds from nerve terminals
Fig. 1 Protein misfolding and protein quality control. Misfolded
proteins are thought to form small toxic oligomers. Molecular
chaperones can facilitate proper protein folding and thus prevent
protein aggregation. Alternatively, if a higher molecular mass
complex of oligomers forms, this may offer protection by avoiding
the toxicity caused by soluble oligomers. UPS-mediated proteasome
degradation can serve as a rapid and efficient pathway to remove
misfolded proteins. Additionally, macroautophagy can enhance the
clearance of misfolded proteins that are poor substrates for the
proteasome, such as highly toxic oligomers and aggregates [174].
Under pathological conditions, reduced activity of protein quality
control systems, such as molecular chaperones, UPS, and autophagy,
leads to accumulation of toxic oligomers, which in turn contributes to
the progression of ‘protein conformational diseases’
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in a Ca2?-dependent manner. After glutamate enters syn-
aptic cleft, it diffuses across the cleft to interact with its
corresponding receptors on the postsynaptic face of an
adjacent neuron. Excitatory neurotransmission is necessary
for the normal development and plasticity of synapses, and
for some forms of learning or memory; however, excessive
activation of glutamate receptors is implicated in neuronal
damage in many neurological disorders ranging from acute
hypoxic-ischemic brain injury to chronic neurodegenerative
diseases. It is currently thought that overstimulation of
extrasynaptic NMDA receptors mediate this neuronal
damage, while, in contrast, synaptic activity predominantly
activates survival pathways [28–30]. Intense hyperstimula-
tion of excitatory receptors leads to necrotic cell death, but
more mild or chronic overstimulation can result in apoptotic
or other forms of cell death [31–33].
There are two large families of glutamate receptors in
the nervous system, ionotropic receptors (representing
ligand-gated ion channels) and metabotropic receptors
(coupled to G-proteins). Ionotropic glutamate receptors are
further divided into three broad classes, NMDA receptors,
a-amino-3-hydroxy-5 methyl-4-isoxazole propionic acid
(AMPA) receptors, and kainate receptors, which are each
named after synthetic ligands that can selectively activate
these receptors. The NMDA receptor has attracted attention
for a long period of time because it has several properties
that set it apart from other ionotrophic glutamate receptors.
One such characteristic, in contrast to most AMPA and
kainate receptors, is that NMDA receptor-coupled channels
are highly permeable to Ca2?, thus permitting Ca2? entry
after ligand binding if the cell is depolarized in order to
relieve block of the receptor-associated ion channel by
Mg2? [34, 35]. Subsequent binding of Ca2? to various
intracellular molecules can lead to many significant con-
sequences. In particular, excessive activation of NMDA
receptors leads to the production of damaging free radicals
(e.g., NO and ROS) and other enzymatic processes, con-
tributing to cell death [10, 15, 32, 33, 36, 37].
Excessive activation of glutamate receptors is implicated
in neuronal damage in many neurological disorders. John
Olney coined the term ‘‘excitotoxicity’’ to describe this
phenomenon [38, 39]. This form of toxicity is mediated at
least in part by excessive activation of NMDA-type recep-
tors [10, 11, 40], resulting in excessive Ca2? influx through
a receptor’s associated ion channel. Increased levels of
neuronal Ca2?, in conjunction with the Ca2?-binding pro-
tein CaM, trigger the activation of nNOS and subsequent
generation of NO from the amino acid L-arginine [12, 41]
(Fig. 2). NO is a gaseous free radical (thus highly diffus-
ible) and a key molecule that plays a vital role in normal
signal transduction but in excess can lead to neuronal cell
damage and death. The discrepancy of NO effects on neu-
ronal survival can also be caused by the formation of
different NO species or intermediates: NO radical (NO),
nitrosonium cation (NO?), nitroxyl anion (NO-, with high
energy singlet and lower energy triplet forms) [15]. Three
subtypes of NOS have been identified; two constitutive
forms of NOS–nNOS and endothelial NOS (eNOS)—take
their names from the cell type in which they were first
found. The name of the third subtype—inducible NOS
(iNOS)—indicates that expression of the enzyme is induced
by acute inflammatory stimuli. For example, activated
microglia may produce neurotoxic amounts of NO via
iNOS expression in various neurodegenerative diseases. All
three isoforms are widely distributed in the brain. Each
NOS isoform contains an oxidase domain at its amino-ter-
minal end and a reductase domain at its carboxy-terminal
end, separated by a Ca2?/CaM binding site [12, 41–44].
Constitutive and inducible NOS are also further distin-
guished by CaM binding: nNOS and eNOS bind CaM in a
reversible Ca2?-dependent manner. In contrast, iNOS binds
CaM so tightly at resting intracellular Ca2? concentrations
that its activity does not appear to be affected by transient
variations in Ca2? concentration. Interestingly, in order to
terminate iNOS-mediated NO production, microglia may
redistribute iNOS to the aggresome for inactivation [45].
Recent studies further pointed out the potential connec-
tion between ROS/RNS and mitochondrial dysfunction in
neurodegenerative diseases, especially in PD [9, 46]. Pes-
ticide and other environmental toxins that inhibit
mitochondrial complex I result in oxidative and nitrosative
stress, and consequent aberrant protein accumulation [17,
18, 20, 47, 48]. Administration to animal models of com-
plex I inhibitors, such as MPTP, 6-hydroxydopamine,
rotenone, and paraquat, which result in overproduction of
ROS/RNS, reproduces many of the features of sporadic PD,
such as dopaminergic neuron degeneration, up-regulation
and aggregation of a-synuclein, Lewy body-like intraneu-
ronal inclusions, and behavioral impairment [9, 46]. In
addition, it has recently been proposed that mitochondrial
cytochrome oxidase can produce NO in a nitrite (NO2
-)-
and pH-dependent but non-Ca2?-dependent manner [49].
Increased nitrosative and oxidative stress are associated
with chaperone and proteasomal dysfunction, resulting in
accumulation of misfolded aggregates [16, 50]. However,
until recently little was known regarding the molecular and
pathogenic mechanisms underlying contribution of NO to
the formation of inclusion bodies such as amyloid plaques
in AD or Lewy bodies in PD.
Nitrosative stress regulates protein misfolding
and neuronal cell death
Extreme nitrosative/oxidative stress can facilitate protein
misfolding and aggregation—and very likely vice-versa.
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This relationship between ROS/RNS and protein misfold-
ing is thought to play a role as a pathogenic trigger of
neurodegenerative diseases, although the exact mechanism
underlying ROS/RNS-mediated aggregate formation has
remained elusive. Recent scientific advances, however,
have implied that NO-related species may significantly
participate in the process of protein misfolding through
protein S-nitrosylation (and possibly nitration) under
degenerative conditions.
Early investigations indicated that NO participates in
cellular signaling pathways, which regulate broad aspects
of brain function, including synaptic plasticity, normal
development, and neuronal cell death [36, 51–53]. In
general, NO exerts physiological and some pathophysio-
logical effects via stimulation of guanylate cyclase to form
cyclic guanosine-30,50-monophosphate (cGMP) or through
S-nitros(yl)ation of regulatory protein thiol groups [13, 15,
50, 54–56]. S-Nitrosylation is the covalent addition of an
NO group to a critical cysteine thiol/sulfhydryl (RSH or,
more properly, thiolate anion, RS-) to form an S-nitroso-
thiol derivative (R-SNO). Such modification modulates the
function of a broad spectrum of mammalian, plant, and
microbial proteins. In general, a consensus motif of amino
acids comprised of nucleophilic residues (generally an acid
and a base) surround a critical cysteine, which increases the
cysteine sulfhydryl’s susceptibility to S-nitrosylation [57,
58]. In contrast, denitrosylating enzymes and pathways,
such as those mediated by thioredoxin/thioredoxin reduc-
tase, PDI, and intracellular glutathione, can decrease the
lifespan of protein SNOs [59–61]. Our group first identified
the physiological relevance of S-nitrosylation by show-
ing that NO and related RNS exert paradoxical effects via
redox-based mechanisms—NO is neuroprotective via
S-nitrosylation of NMDA receptors (as well as other sub-
sequently discovered targets, including caspases), and yet
can also be neurodestructive by formation of peroxynitrite
(or, as later discovered, reaction with additional molecules
such as MMP-9 and GAPDH) [15, 62–69]. Over the past
decade, accumulating evidence has suggested that S-nit-
rosylation can regulate the biological activity of a great
variety of proteins, in some ways akin to phosphorylation
[15, 17, 18, 20, 58, 68–76]. Chemically, NO is often a good
‘‘leaving group,’’ facilitating further oxidation of critical
thiol to disulfide bonds among neighboring (vicinal) cys-
teine residues or, via reaction with ROS, to sulfenic
(–SOH), sulfinic (–SO2H) or sulfonic (–SO3H) acid
derivatization of the protein [18, 20, 68, 77]. Alternatively,
S-nitrosylation may possibly produce a nitroxyl disulfide,
in which the NO group is shared by close cysteine thiols [78].
Analyses of mice deficient in either nNOS or iNOS
confirmed that NO is an important mediator of cell injury
and death after excitotoxic stimulation; NO generated from
nNOS or iNOS is detrimental to neuronal survival [79, 80].
In addition, inhibition of NOS activity ameliorates the
progression of disease pathology in animal models of PD,
AD, and ALS, suggesting that excess generation of NO
plays a pivotal role in the pathogenesis of several neuro-
degenerative diseases [81–84]. Intriguingly, levels of
glutathione diminish by *30% in the aged brain [85],
potentially assisting the accumulation of SNOs in elderly.
Although the involvement of NO in neurodegeneration has
been widely accepted, the chemical relationship between
nitrosative stress and accumulation of misfolded proteins
has remained obscure. Recent findings, however, have shed
light on molecular events underlying this relationship.
Specifically, we recently mounted physiological and
chemical evidence that S-nitrosylation modulates the (1)
ubiquitin E3 ligase activity of parkin [17–19], and (2)
chaperone and isomerase activities of PDI [20], contrib-
uting to protein misfolding and neurotoxicity in models of
neurodegenerative disorders.
Additionally, peroxynitrite-mediated nitration of tyro-
sine residue(s) may potentially contribute to dysfunctional
protein folding and neuronal cell injury. For instance,
nitration of a-synuclein and tau effects oligomer formation
in vitro. Furthermore, it has been reported that nitrated
a-synuclein and tau selectively accumulate in inclusion
bodies in PD and neurofibrillary tangles in AD brains
[86–89]. Collectively, these findings support the proposi-
tion that S-nitrosylation and possibly nitration can
influence aggregate formation and neurotoxicity.
Parkin and the UPS
Recent studies on rare genetic forms of PD have found that
mutations in the genes encoding parkin (PARK2), PINK1
(PARK6), a-synuclein (PARK1/4), DJ-1 (PARK7), ubiqui-
tin C-terminal hydrolase L1 (UCH-L1) (PARK5), leucine-
rich repeat kinase-2 (LRRK2) (PARK8), or ATP13A2
(PARK9) are associated with PD pathology [90–97]. The
discovery that mutations in these genes predispose patients
to very rare familial forms of PD have allowed us to begin
to understand the mechanism of protein aggregation and
neuronal loss in the more common sporadic forms of PD.
For instance, the identification of a-synuclein as a famil-
ial PD gene led to the recognition that one of the major
constituents of Lewy bodies in sporadic PD brains is
a-synuclein. In addition, identification of errors in the
genes encoding parkin (a ubiquitin E3 ligase) and UCH-L1
in rare familial forms of PD has implicated possible dys-
function of the UPS in the pathogenesis of sporadic PD as
well. The UPS represents an important mechanism for
proteolysis in mammalian cells. Formation of polyubiquitin
chains constitutes the signal for proteasomal attack and
degradation. An isopeptide bond covalently attaches the C
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terminus of the first ubiquitin in a polyubiqutin chain to a
lysine residue in the target protein. The cascade of acti-
vating (E1), conjugating (E2), and ubiquitin-ligating (E3)
type enzymes catalyzes the conjugation of the ubiquitin
chain to proteins. In addition, individual E3 ubiquitin
ligases play a key role in the recognition of specific sub-
strates [98].
Mutations in the parkin gene can cause autosomal
recessive juvenile Parkinsonism (ARJP), accounting for
some cases of hereditary PD manifest in young patients
with onset beginning anywhere from the teenage years
through the 40s [22, 90, 99]. Parkin is a member of a large
family of E3 ubiquitin ligases that are related to one
another by the presence of RING finger domains. Parkin
contains a total of 35 cysteine residues, the majority of
which reside within its RING domains, which coordinate a
structurally important zinc atom often involved in catalysis
[100]. Parkin has two RING finger domains separated by
an ‘‘in between RING’’ (IBR) domain. This motif allows
parkin to recruit substrate proteins as well as an E2 enzyme
(e.g., UbcH7, UbcH8, or UbcH13). Point mutations, stop
mutations, truncations, and deletions in both alleles of the
parkin gene will eventually cause dysfunction in its
activity and are responsible for many cases of ARJP as
well as rare adult forms of PD. Parkin mutations usually do
not facilitate the formation of Lewy bodies, although there
is at least one exception—familial PD patients with the
R275W parkin mutant manifest Lewy bodies [101]. Bio-
chemical characterization of parkin mutants show that not
all parkin mutations result in loss of parkin E3 ligase
activity; some of the familial-associated parkin mutants
(e.g., the R275W mutant) have increased ubiquitination
activity compared to wild-type [102–104]. Additionally,
parkin can mediate the formation of non-classical and
‘‘non-degradative’’ lysine 63-linked polyubiquitin chains
[105, 106]. Likewise, parkin can mono-ubiquitinates
Eps15, HSP70, and itself possibly at the multiple sites.
This finding may explain how some parkin mutations
induce formation of Lewy bodies and why proteins are
stabilized within the inclusions.
Several putative target substrates have been identified
for parkin E3 ligase activity. One group has reported that
mutant parkin failed to bind glycosylated a-synuclein for
ubiquitination, leading to a-synuclein accumulation [107],
but most authorities do not feel that a-synuclein is a direct
substrate of parkin. Synphilin-1 (a-synuclein interacting
protein), on the other hand, is considered to be a substrate
for parkin ubiquitination, and it is included in Lewy body-
like inclusions in cultured cells when co-expressed with
a-synuclein [108]. Other substrates for parkin include
parkin-associated endothelin receptor-like receptor (Pael-
R) [109], cell division control related protein (CDCrel-1)
[110], cyclin E [111], p38 tRNA synthase [112], and syn-
aptotagmin XI [113], a/b tubulin heterodimers [114], as
well as possibly parkin itself (auto-ubiquitination). It is
generally accepted that accumulation of these substrates
can lead to disastrous consequences for the survival of
dopaminergic neurons in familial PD and possibly also in
sporadic PD. Therefore, characterization of potential reg-
ulators that affect parkin E3 ligase activity may reveal
important molecular mechanisms for the pathogenesis of
PD. Heretofore, two cellular components have been shown
to regulate the substrate specificity and ubiquitin E3 ligase
activity of parkin. The first represents posttranslational
modification of parkin through S-nitrosylation or phos-
phorylation [115], and the second, binding partners of
parkin, such as CHIP [116] and BAG5 [117]. CHIP
enhances the ability of parkin to inhibit cell death through
up-regulation of parkin-mediated ubiquitination, while
BAG5-mediated inhibition of parkin E3 ligase activity
facilitates neuronal cell death. In addition, several groups
have recently reported that parkin-mediated mono-ubiqui-
tination could contribute to neuronal survival via a
proteasome-independent pathway [103, 104, 118, 119]. For
Fig. 2 Possible mechanism whereby S-nitrosylated species contrib-
ute to the accumulation of aberrant proteins and neuronal damage.
NMDAR hyperactivation triggers generation of NO/ROS and cyto-
chrome C release from mitochondria associated with subsequent
activation of caspases, causing neuronal cell damage and death.
S-Nitrosylation of parkin (forming SNO-PARK) and PDI (forming
SNO-PDI) can contribute to neuronal cell injury in part by triggering
accumulation of misfolded proteins. Memantine and NitroMemantine
preferentially block excessive (pathological/extrasynatpic) NMDAR
activity while relatively sparing normal (physiological/synaptic)
activity
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example, parkin mono-ubiquitinates the epidermal growth
factor receptor (EGFR)-associated protein, Eps15, leading
to inhibition of EGFR endocytosis [118]. The resulting
prolongation of EGFR signaling via the phosphoinositide-3
kinase/Akt (PKB) signaling pathway is postulated to
enhance neuronal survival.
Another important molecule that links aberrant UPS
activity and PD is the ubiquitin hydrolase Uch-L1, a
deubiquitinating enzyme that recycles ubiquitin. Autoso-
mal dominant mutations of Uch-L1 have been identified in
two siblings with PD [94]. Interestingly, a recent study
suggested that a novel ubiquitin-ubiquitin ligase activity of
Uch-L1 might also be important in the pathogenesis of PD
[120]. Additional mutations in a-synuclein, DJ-1, PINK1,
and LRRK2 may contribute to UPS dysfunction and sub-
sequently lead to PD.
S-Nitrosylation and parkin
PD is the second most prevalent neurodegenerative disease
and is characterized by the progressive loss of dopamine
neurons in the substantia nigra pars compacta. Appearance
of Lewy bodies that contain misfolded and ubiquitinated
proteins generally accompanies the loss of dopaminergic
neurons in the PD brain. Such ubiquitinated inclusion
bodies are the hallmark of many neurodegenerative dis-
orders. Age-associated defects in intracellular proteolysis
of misfolded or aberrant proteins might lead to accumu-
lation and ultimately deposition of aggregates within
neurons or glial cells. Although such aberrant protein
accumulation had been observed in patients with geneti-
cally encoded mutant proteins, recent evidence from our
laboratory suggests that nitrosative and oxidative stress are
potential causal factors for protein accumulation in the
much more common sporadic form of PD. As illustrated
below, nitrosative/oxidative stress, commonly found dur-
ing normal aging, can mimic rare genetic causes of
disorders, such as PD, by promoting protein misfolding in
the absence of a genetic mutation [17–19]. For example,
S-nitrosylation and further oxidation of parkin or Uch-L1
result in dysfunction of these enzymes and thus of the UPS
[17, 18, 121–124]. We and others recently discovered that
nitrosative stress triggers S-nitrosylation of parkin (form-
ing SNO-parkin) not only in rodent models of PD but also
in the brains of human patients with PD and the related
a-synucleinopathy, DLBD (diffuse Lewy body disease).
SNO-parkin initially stimulates ubiquitin E3 ligase activ-
ity, resulting in enhanced ubiquitination as observed in
Lewy bodies, followed by a decrease in enzyme activity,
producing a futile cycle of dysfunctional UPS [18, 19,
105] (Fig. 2). We also found that rotenone led to the
generation of SNO-parkin and thus dysfunctional ubiquitin
E3 ligase activity. Moreover, S-nitrosylation appears to
compromise the neuroprotective effect of parkin [17].
These mechanisms involve S-nitrosylation of critical cys-
teine residues in the first RING domain of parkin [18].
Nitrosative and oxidative stress can also alter the solubility
of parkin via posttranslational modification of cysteine
residues, which may concomitantly compromise its pro-
tective function [125–127]. Additionally, it is likely that
other ubiquitin E3 ligases with RING-finger thiol motifs
are S-nitrosylated in a similar manner to parkin to affect
their enzymatic function; hence, S-nitrosylation of E3
ligases may be involved in a number of degenerative
conditions.
The neurotransmitter dopamine (DA) may also impair
parkin activity and contribute to neuronal demise via the
modification of cysteine residue(s) [128]. DA can be oxi-
dized to DA quinone, which can react with and inactivate
proteins through covalent modification of cysteine sulfhy-
dryl groups; peroxynitrite has been reported to promote
oxidation of DA to form dopamine quinone [129]. DA
quinone can preferentially attack cysteine residues (C268
and C323) in the RING1 and IBR domains of parkin,
forming a covalent adduct that abrogates its E3 ubiquitin
ligase activity [126, 128]. DA quinone also reduces the
solubility of parkin, possibly inducing parkin misfolding
after disruption of the RING-IBR-RING motif. Therefore,
oxidative/nitrosative species may either directly or indi-
rectly contribute to altered parkin activity within the brain,
and subsequent loss of parkin-dependent neuroprotection
results in increased cell death.
The unfolded protein response (UPR) and PDI
The ER normally participates in protein processing and
folding but undergoes a stress response when immature or
misfolded proteins accumulate [130–133]. ER stress stim-
ulates two critical intracellular responses. The first
represents expression of chaperones that prevent protein
aggregation via the UPR, and is implicated in protein
refolding, post-translational assembly of protein com-
plexes, and protein degradation. This response is believed
to contribute to adaptation during altered environmental
conditions, promoting maintenance of cellular homeostasis.
At least three ER transmembrane sensor proteins are
involved in the UPR: PKR-like ER kinase (PERK), acti-
vating transcription factor 6 (ATF6), and inositol-requiring
enzyme 1 (IRE1). The activation of all three proximal
sensors results in the attenuation of protein synthesis via
eukaryotic initiation factor-2 (eIF2) kinase and increased
protein folding capacity of the ER [134–137]. The second
ER stress response, termed ER-associated degradation
(ERAD), specifically recognizes terminally misfolded
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proteins for retro-translocation across the ER membrane to
the cytosol, where they can be degraded by the UPS.
Additionally, although severe ER stress can induce apop-
tosis, the ER withstands relatively mild insults via
expression of stress proteins such as glucose-regulated
protein (GRP) and PDI. These proteins behave as molec-
ular chaperones that assist in the maturation, transport, and
folding of secretory proteins.
During protein folding in the ER, PDI can introduce
disulfide bonds into proteins (oxidation), break disulfide
bonds (reduction), and catalyze thiol/disulfide exchange
(isomerization), thus facilitating disulfide bond formation,
rearrangement reactions, and structural stability [138]. PDI
has four domains that are homologous to thioredoxin
(TRX) (termed a, b, b0, and a0). Only two of the four TRX-
like domains (a and a0) contain a characteristic redox-active
CXXC motif, and these two-thiol/disulfide centers function
as independent active sites [139–142]. These active-site
cysteines can be found in two different redox states: oxi-
dized (disulfide) or reduced (free sulfhydryls or thiols).
During oxidation of a target protein, oxidized PDI cata-
lyzes disulfide formation in the substrate protein, resulting
in the reduction of PDI. In contrast, the reduced form of the
active-site cysteines can initiate isomerization by attacking
the disulfide of a substrate protein and forming a transient
intermolecular disulfide bond. As a consequence, an
intramolecular disulfide rearrangement occurs within the
substrate itself, resulting in the generation of reduced PDI.
The recently determined structure of yeast PDI revealed
that the four TRX-like domains form a twisted ‘‘U’’ shape
with the two active sites facing each other on opposite sides
of the ‘‘U’’ [143]. Hydrophobic residues line the inside
surface of the ‘‘U,’’ facilitating interactions between PDI
and misfolded proteins. Specifically, the b0 domain of PDI
constitutes a part of the base of the ‘‘U’’ shaped structure
and contributes to the efficient binding of misfolded pro-
teins [144]. Several mammalian PDI homologues, such as
ERp57 and PDIp, also localize to the ER and may manifest
similar functions [145, 146]. Increased expression of PDIp
in neuronal cells under conditions mimicking PD suggest
the possible contribution of PDIp to neuronal survival
[145]. Additionally, ERdj5, an ER reductase that contains
four TRX-like domains, forms a functional ERAD complex
with GRP, promoting the degradation of misfolded proteins
via ERAD [147].
In many neurodegenerative disorders and cerebral
ischemia, the accumulation of immature and denatured
proteins results in ER dysfunction [145, 148–150], but up-
regulation of PDI represents an adaptive response pro-
moting protein refolding and may offer neuronal cell
protection [145, 146, 151, 152]. In a recent study, we
reported that the S-nitrosylation of PDI (to form SNO-PDI)
disrupts its neuroprotective role [20].
S-Nitrosylation of PDI mediates protein misfolding
and neurotoxicity in cell models of PD or AD
Disturbance of Ca2? homeostasis within the ER plays a
critical role in the accumulation of misfolded proteins and
ER stress because the function of several ER chaperones
requires high concentrations of Ca2?. In addition, it is
generally accepted that excessive generation of NO can
contribute to activation of the ER stress pathway, at least in
some cell types [153, 154]. Molecular mechanisms by
which NO induces protein misfolding and ER stress,
however, have remained enigmatic until recently. The ER
normally manifests a relatively positive redox potential in
contrast to the highly reducing environment of the cytosol
and mitochondria. This redox environment can influence
the stability of protein S-nitrosylation and oxidation reac-
tions [155]. S-Nitrosylation can enhance the activity of the
ER Ca2? channel-ryanodine receptor [156], which may
provide a clue to how NO disrupts Ca2? homeostasis in the
ER and activates the cell death pathway. Interestingly, we
have recently reported that excessive NO can also lead to
S-nitrosylation of the active-site thiol groups of PDI, and
this reaction inhibits both its isomerase and chaperone
activities [20]. Mitochondrial complex I insult by rotenone
can also result in S-nitrosylation of PDI in cell culture
models. Moreover, we found that PDI is S-nitrosylated in
the brains of virtually all cases examined of sporadic AD
and PD. Under pathological conditions, it is possible that
both cysteine sulfhydryl groups in the TRX-like domains of
PDI form SNOs. Unlike formation of a single SNOs which
is commonly seen after de-nitrosylation reactions catalyzed
by PDI [72], dual nitrosylation may be relatively more
stable and prevent subsequent disulfide formation on PDI.
Therefore, we speculate that these pathological S-nitrosy-
lation reactions on PDI are more easily detected during
neurodegenerative conditions. Additionally, it is possible
that vicinal (nearby) cysteine thiols reacting with NO can
form nitroxyl disulfide [78], and such reaction may
potentially occur in the catalytic side of PDI to inhibit
enzymatic activity. In order to determine the consequences
of S-nitrosylated PDI (SNO-PDI) formation in neurons, we
exposed cultured cerebrocortical neurons to neurotoxic
concentrations of NMDA, thus inducing excessive Ca2?
influx and consequent NO production from nNOS. Under
these conditions, we found that PDI was S-nitrosylated in a
NOS-dependent manner. SNO-PDI formation led to the
accumulation of polyubiquitinated/misfolded proteins and
activation of the UPR. Moreover, S-nitrosylation abrogated
the inhibitory effect of PDI on aggregation of proteins
observed in Lewy body inclusions [20, 108]. S-Nitrosyla-
tion of PDI also prevented its attenuation of neuronal cell
death triggered by ER stress, misfolded proteins, or pro-
teasome inhibition (Fig. 2). Further evidence suggested
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that SNO-PDI may in effect transport NO to the extracel-
lular space, where it could conceivably exert additional
adverse effects [72]. Additionally, NO can possibly medi-
ate cell death or injury via S-nitrosylation or nitration
reactions on other TRX-like proteins, such as TRX itself
and glutaredoxin [71, 157, 158].
In addition to PDI, S-nitrosylation is likely to affect
critical thiol groups on other chaperones, such as HSP90 in
the cytoplasm [159] and possibly GRP in the ER. Nor-
mally, HSP90 stabilizes misfolded proteins and modulates
the activity of cell signaling proteins including NOS and
calcineurin [2]. In AD brains, levels of HSP90 are
increased in both the cytosolic and membranous fractions,
where HSP90 is thought to maintain tau and Ab in a sol-
uble conformation, thereby averting their aggregation [160,
161]. Martı´nez-Ruiz et al. [159] recently demonstrated that
S-nitrosylation of HSP90 can occur in endothelial cells, and
this modification abolishes its ATPase activity, which is
required for its function as a molecular chaperone. These
studies imply that S-nitrosylation of HSP90 in neurons of
AD brains may contribute to the accumulation of tau and
Ab aggregates.
The UPS is apparently impaired in the aging brain.
Additionally, inclusion bodies similar to those found in
neurodegenerative disorders can appear in brains of normal
aged individuals or those with subclinical manifestations of
disease [162]. These findings suggest that the activity of the
UPS and molecular chaperones may decline in an age-
dependent manner [163]. Given that we have not found
detectable quantities of SNO-parkin and SNO-PDI in
normal aged brain [17, 18, 20] we speculate that S-nitro-
sylation of these and similar proteins may represent a key
event that contributes to susceptibility of the aging brain to
neurodegenerative conditions.
Potential treatment of excessive NMDA-induced Ca21
influx and free radical generation
One mechanism that could potentially curtail excessive
Ca2? influx and resultant overstimulation of nNOS activity
would be inhibition of NMDA receptors. Until recently,
however, drugs in this class blocked virtually all NMDA
receptor activity, including physiological activity, and
therefore manifest unacceptable side effects by inhibiting
normal functions of the receptor. For this reason, many
previous NMDA receptor antagonists have disappointingly
failed in advanced clinical trials conducted for a number of
neurodegenerative disorders. In contrast, studies in our
laboratory first showed that the adamantine derivative,
memantine, preferentially blocks excessive (pathological)
NMDA receptor activity while relatively sparing normal
(physiological) activity (Fig. 2). Memantine does this in a
surprising fashion because of its low (micromolar) affinity,
even though its actions are quite selective for the NMDA
receptor at that concentration. ‘‘Apparent’’ affinity of a
drug is determined by the ratio of its ‘‘on-rate’’ to its ‘‘off-
rate’’ for the target. The on-rate is not only a property of
drug diffusion and interaction with the target, but also the
drug’s concentration. In contrast, the off-rate is an intrinsic
property of the drug-receptor complex, unaffected by drug
concentration. A relatively fast off-rate is a major con-
tributor to memantine’s low affinity for the NMDA
receptor. The inhibitory activity of memantine involves
blockade of the NMDA receptor-associated ion channel
when it is excessively open (termed open-channel block).
The unique and subtle difference of the memantine
blocking sites in the channel pore may explain the advan-
tageous properties of memantine action.
Also critical for the clinical tolerability of memantine is
its uncompetitive mechanism of action. An uncompetitive
antagonist can be distinguished from a noncompetitive
antagonist, which acts allosterically at a noncompetitive
site, i.e., at a site other than the agonist-binding site. An
uncompetitive antagonist is defined as an inhibitor whose
action is contingent upon prior activation of the receptor by
the agonist. Hence, the same amount of antagonist blocks
higher concentrations of agonist relatively better than
lower concentrations of agonist. Some open-channel
blockers function as pure uncompetitive antagonists,
depending on their exact properties of interaction with the
ion channel. This uncompetitive mechanism of action
coupled with a relatively fast off-rate from the channel
yields a drug that preferentially blocks NMDA receptor-
operated channels when they are excessively open while
relatively sparing normal neurotransmission. In fact, the
relatively fast off-rate is a major contributor to a drug like
memantine’s low affinity for the channel pore. While many
factors determine a drug’s clinical efficacy and tolerability,
it appears that the relatively rapid off rate is a predominant
factor in memantine’s tolerability in contrast to other
NMDA-type receptor antagonists.[11, 40] Thus, the critical
features of memantine’s mode of action are its uncompet-
itive mechanism and fast off-rate, or what we call a UFO
drug—a drug that is present at its site of inhibitory action
only when you need it and then quickly disappears.
Interestingly, memantine, which is chemically an ada-
mantine, was first synthesized and patented in 1968 by Eli
Lilly and Company, as described in the Merck Index.
Memantine has been used for many years in Europe to treat
PD, spasticity, convulsions, vascular dementia, and later
AD [164, 165]. Interestingly, the efficacy of adamantine-
type drugs in the brain was first discovered by serendipity
in a patient taking amantadine for influenza (amantadine is
chemically similar to memantine but lacks two side groups
chains composed of methyl groups). This led scientists to
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believe that these drugs were dopaminergic or possibly
anti-cholinergic, although, as stated above, we later dis-
covered that memantine acts as an open-channel blocker of
NMDA receptor (NMDAR)-coupled channel pore; me-
mantine is more potent in this action than amantadine. A
large number of studies with in vitro and in vivo animal
models demonstrated that memantine protects cerebrocor-
tical neurons, cerebellar neurons, and retinal neurons from
NMDAR-mediated excitotoxic damage [166–170]. Impor-
tantly, in a rat stroke model, memantine, which was given
up to 2 h after the ischemic event, reduced the amount of
brain damage by *50% [167, 168]. Furthermore, regula-
tory agencies in both Europe and the USA recently voted
its approval as the first treatment for moderate-to-severe
AD. It is currently under study for a number of other
neurodegenerative disorders, including HIV-associated
dementia, Huntington’s disease, ALS and also depression.
As promising as the results with memantine are, we are
continuing to pursue ways to use additional modulatory
sites on the NMDA receptor to block excitotoxicity even
more effectively and safely than memantine alone. New
approaches in this regard are explored below.
Future therapeutics: NitroMemantines
NitroMemantines are second-generation memantine deriv-
atives that are designed to have enhanced neuroprotective
efficacy without sacrificing clinical tolerability. S-Nitro-
sylation site(s) is located on the extracellular domain of the
NMDA receptor, and S-nitrosylation of this site, i.e., NO
reaction with the sulfhydryl group of a critical cysteine
residue, down-regulates (but does not completely shut off)
receptor activity [11, 21]. The drug nitroglycerin, which
generates NO-related species, can act at this site to limit
excessive NMDA receptor activity. In fact, in rodent
models, nitroglycerin can limit ischemic damage [171], and
there is some evidence that patients taking nitroglycerin for
other medical reasons may be resistant to glaucomatous
visual field loss [172]. Consequently, we carefully char-
acterized the S-nitrosylation sites on the NMDA receptor in
order to determine if we could design a nitroglycerin-like
drug that could be more specifically targeted to the
receptor. In brief, we found that five different cysteine
residues on the NMDA receptor could interact with NO.
One of these, located at cysteine residue #399 (Cys399) on
the NR2A subunit of the NMDA receptor, mediates C90%
of the effect of NO under our experimental conditions [67].
From crystal structure models and electrophysiological
experiments, we further found that NO binding to the
NMDA receptor at Cys399 may induce a conformational
change in the receptor protein that makes glutamate and
Zn2? bind more tightly to the receptor. The enhanced
binding of glutamate and Zn2? in turn causes the receptor
to desensitize and, consequently, the ion channel to close
[76]. Electrophysiological studies have demonstrated this
inhibitory effect of NO on the NMDA receptor-associated
channel [15, 55, 67]. Moreover, as the oxygen tension is
lowered (a pO2 of 10–20 torr is found in normal brain, and
even lower levels under hypoxic/ischemic conditions), the
NMDA receptor becomes more sensitive to inhibition by
S-nitrosylation [173].
Unfortunately, nitroglycerin itself is not very attractive
as a neuroprotective agent. The same cardiovascular
vasodilator effect that makes it useful in the treatment of
angina could cause dangerously large drops in blood
pressure in patients with dementia, stroke, traumatic injury,
or glaucoma. However, the open-channel block mechanism
of memantine not only leads to a higher degree of channel
blockade in the presence of excessive levels of glutamate
but also can be used as a homing signal for targeting drugs,
e.g., the NO group, to hyperactivated, open NMDA-gated
channels. We have therefore been developing combinato-
rial drugs (NitroMemantines) that theoretically should be
able to use memantine to target NO to the nitrosylation
sites of the NMDAR in order to avoid the systemic side
effects of NO. Two sites of modulation would be analogous
to having two volume controls on your television set for
fine-tuning the audio signal.
Preliminary studies have shown NitroMemantines to be
highly neuroprotective in both in vitro and in vivo animal
models [11]. In fact, they appear to be more effective than
memantine at lower dosage. Moreover, because of the
targeting effect of the memantine moiety, NitroMeman-
tines appear to lack the blood pressure lowering effects
typical of nitroglycerin. More research still needs to be
performed on NitroMemantine drugs, but by combining
two clinically tolerated drugs (memantine and nitroglyc-
erin), we have created a new, improved class of UFO drugs
that should be both clinically tolerated and neuroprotective.
Conclusions
Excessive nitrosative and oxidative stress triggered by
excessive NMDA receptor activation and/or mitochondrial
dysfunction may result in malfunction of the UPS or
molecular chaperones, thus contributing to abnormal pro-
tein accumulation and neuronal damage in sporadic forms
of neurodegenerative diseases. Our elucidation of an NO-
mediated pathway to dysfunction of parkin and PDI by
S-nitrosylation provides a mechanistic link between free
radical production, abnormal protein accumulation, and
neuronal cell injury in neurodegenerative disorders such as
PD. Elucidation of this new pathway may lead to the
development of additional new therapeutic approaches to
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prevent aberrant protein misfolding by targeted disruption
or prevention of nitrosylation of specific proteins such as
parkin and PDI. This article also describes the action of
memantine via uncompetitive antagonism of the NMDA
receptor with a fast off-rate. NitroMemantines enhance the
neuroprotective efficacy over memantine at a given dose
owing to its additional ability to S-nitrosylate the NMDA
receptor. These drugs preferentially inhibit pathologically
activated NMDA receptor while preserving its normal
synaptic function; thus, they are clinically tolerated. In this
chapter we propose that the next generation of CNS drugs
will interact with their target only during states of patho-
logical activation and not interfere with the target if it is
functioning properly. In the future, such perspectives
should lead to additional novel, clinically tolerated neuro-
protective therapeutics.
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